Cubist Systematic Strategies’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-46,602
Closed -$5.97M 3030
2025
Q2
$5.97M Buy
+46,602
New +$4.84M 0.03% 908
2024
Q3
Sell
-4,901
Closed -$487K 3009
2024
Q2
$528K Buy
+4,901
New +$491K ﹤0.01% 2101
2022
Q4
Sell
-28,037
Closed -$1.85M 4259
2022
Q3
$1.85M Sell
28,037
-19,576
-41% -$1.26M 0.01% 2084
2022
Q2
$2.4M Buy
47,613
+16,169
+51% +$947K 0.01% 1672
2022
Q1
$2.01M Buy
31,444
+22,745
+261% +$1.63M 0.02% 1479
2021
Q4
$932K Buy
8,699
+8,076
+1,296% +$845K 0.01% 1969
2021
Q3
$64K Sell
623
-36,404
-98% -$3.39M ﹤0.01% 2813
2021
Q2
$3.26M Buy
37,027
+23,251
+169% +$2.13M 0.04% 785
2021
Q1
$1.34M Sell
13,776
-21,402
-61% -$2.14M 0.02% 1329
2020
Q4
$3.94M Buy
35,178
+31,721
+918% +$3.34M 0.05% 552
2020
Q3
$320K Sell
3,457
-199
-5% -$15.3K ﹤0.01% 1963
2020
Q2
$285K Sell
3,656
-12,494
-77% -$845K ﹤0.01% 1870
2020
Q1
$944K Buy
16,150
+3,602
+29% +$232K 0.03% 870
2019
Q4
$1M Buy
12,548
+2,540
+25% +$190K 0.02% 1156
2019
Q3
$735K Buy
+10,008
New +$865K 0.01% 1125
2019
Q2
Sell
-7,212
Closed -$577K 2453
2019
Q1
$577K Buy
+7,212
New +$533K 0.02% 1095
2018
Q4
Sell
-3,520
Closed -$275K 2060
2018
Q3
$275K Buy
+3,520
New +$245K 0.02% 1217
2018
Q2
Sell
-200
Closed -$18K 1793
2018
Q1
$18K Sell
200
-972
-83% -$83.8K ﹤0.01% 1752
2017
Q4
$88K Buy
1,172
+1,126
+2,448% +$79.2K ﹤0.01% 1700
2017
Q3
$3K Sell
46
-791
-95% -$42.3K ﹤0.01% 1802
2017
Q2
$42K Sell
837
-1,894
-69% -$80.4K ﹤0.01% 1561
2017
Q1
$109K Buy
+2,731
New +$97.8K 0.01% 1375

Other funds holding BPMC

Cubist Systematic Strategies's BPMC Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 46,602 shares — an estimated $5.97M sold.

Cubist Systematic Strategies first reported a position in BPMC in Q1 2017 and held it in 22 quarters. The position peaked at $5.97M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 46,602 Blueprint Medicines shares in Q3 2025, an estimated $5.97M.
  • Cubist Systematic Strategies first reported a position in Blueprint Medicines in Q1 2017 and held it in 22 quarters.
  • Cubist Systematic Strategies's Blueprint Medicines position peaked at $5.97M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.